LB Pharmaceuticals Net Income From Continuing Ops Over Time
| LBRX Stock | 21.16 0.08 0.38% |
With this module, investors can use any or all of fundamental ratio historical patterns as a complementary method for asset selection as well as a tool for deciding entry and exit points. Many technical investors use fundamentals to limit their universe of possible portfolio assets.
Check out LB Pharmaceuticals Performance and LB Pharmaceuticals Correlation. Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of LB Pharmaceuticals. Expected growth trajectory for LBRX significantly influences the price investors are willing to assign. The financial industry is built on trying to define current growth potential and future valuation accurately. Comprehensive LB Pharmaceuticals assessment requires weighing all these inputs, though not all factors influence outcomes equally.
Understanding LB Pharmaceuticals Common requires distinguishing between market price and book value, where the latter reflects LBRX's accounting equity. The concept of intrinsic value—what LB Pharmaceuticals' is actually worth based on fundamentals—guides informed investors toward better entry and exit points. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Market sentiment, economic cycles, and investor behavior can push LB Pharmaceuticals' price substantially above or below its fundamental value.
Understanding that LB Pharmaceuticals' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether LB Pharmaceuticals represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. In contrast, LB Pharmaceuticals' trading price reflects the actual exchange value where willing buyers and sellers reach mutual agreement.
Cross Equities Net Income From Continuing Ops Analysis
Compare LB Pharmaceuticals Common and related stocks such as Rocket Pharmaceuticals, Aura Biosciences, and Annexon Net Income From Continuing Ops Over Time
Select Fundamental| 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| RCKT | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (9.5 M) | (68 M) | (42.9 M) | (29.5 M) | (74.7 M) | (77.5 M) | (139.7 M) | (169.1 M) | (221.9 M) | (252.7 M) | (258.7 M) | (232.9 M) | (221.2 M) |
| AURA | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (24.2 M) | (22.2 M) | (35.3 M) | (58.8 M) | (70.8 M) | (86.9 M) | (78.2 M) | (82.1 M) |
| ANNX | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (18.3 M) | (37.2 M) | (63.4 M) | (130.7 M) | (145.6 M) | (140.7 M) | (138.2 M) | (124.4 M) | (130.6 M) |
| SLDB | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (6.7 M) | (23.8 M) | (53.2 M) | (74.8 M) | (117.2 M) | (88.3 M) | (72.2 M) | (86 M) | (90.8 M) | (124.7 M) | (112.2 M) | (117.8 M) |
| LRMR | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (23.1 M) | (42.5 M) | (50.6 M) | (35.4 M) | (36.9 M) | (80.6 M) | (72.5 M) | (68.9 M) |
| ALT | (3.8 M) | (3.8 M) | (4.9 M) | (11.7 M) | (10 M) | (3.4 M) | 193.9 M | (46.4 M) | (39.2 M) | (20.5 M) | (49 M) | (97.1 M) | (84.7 M) | (88.4 M) | (95.1 M) | (85.6 M) | (81.3 M) |
| AUTL | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (44.8 M) | (4.9 M) | (12.6 M) | (19.7 M) | (57.9 M) | (123.8 M) | (142.1 M) | (142.1 M) | (148.8 M) | (158.2 M) | (220.7 M) | (198.6 M) | (188.7 M) |
| DBVT | (19.3 M) | (19.3 M) | (19.3 M) | (19.3 M) | (24 M) | (57.2 M) | (114.5 M) | (147.7 M) | (166.1 M) | (153.6 M) | (159.6 M) | (97.8 M) | (96.3 M) | (100.8 M) | (113.9 M) | (102.5 M) | (107.7 M) |
| DSGN | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (2 M) | (8.3 M) | (35.5 M) | (63.3 M) | (72.4 M) | (49.6 M) | (44.6 M) | (46.9 M) |
| KRRO | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (22 M) | (58 M) | (81.2 M) | (83.6 M) | (75.2 M) | (79 M) |
LB Pharmaceuticals Common and related stocks such as Rocket Pharmaceuticals, Aura Biosciences, and Annexon Net Income From Continuing Ops description
My Equities
My Current Equities and Potential Positions
| LB Pharmaceuticals Common | LBRX |
Specialization | Healthcare, Biotechnology |
| Business Address | One Pennsylvania Plaza, |
| Exchange | NASDAQ Exchange |
null 21.16
Additional Tools for LBRX Stock Analysis
When running LB Pharmaceuticals' price analysis, check to measure LB Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy LB Pharmaceuticals is operating at the current time. Most of LB Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of LB Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move LB Pharmaceuticals' price. Additionally, you may evaluate how the addition of LB Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.